The Democratic Republic of Congo has recorded 10,060 Ebola cases and 4,887 deaths linked to an outbreak first detected in mid-May. The cause is the Bundibugyo virus. No licensed vaccine and no targeted medicine have been approved for it. Africa CDC has applied a stark label to the epidemic:
“fastest-growing Ebola outbreak in history”
Infections connected to the same outbreak have also been confirmed in Kenya and Nigeria.
- Key Point: Congo’s tally stands at 10,060 cases and 4,887 deaths; Bundibugyo is the strain, and no vaccine or targeted drug has been authorized for it.
- Key Point: Kenya has nine infections, two fatal, after a patient came from Congo through Uganda to Nairobi.
- Key Point: Nigeria’s single case is a Swiss woman married to a Swiss diplomat; she became sick after a trip to Uganda and was flown to Switzerland.
- Key Point: Two antiviral treatment strategies have been in trials since July, while two more studies test whether Ervebo can guard against Bundibugyo.
Congo’s numbers and the Bundibugyo problem
The Congo caseload remains the core of the emergency. The count of 10,060 cases and 4,887 deaths dates from mid-May, when the outbreak was recognized. Africa CDC’s description emphasizes both speed and scale.
Bundibugyo is not covered by a licensed vaccine, and no specific therapy has been approved to treat it. That absence shapes the response: clinicians cannot rely on a strain-matched preventive tool or a targeted drug. The outbreak is therefore harder to suppress, because the usual package of proven biomedical tools is incomplete. The point is not that no care exists; it is that the response lacks a vaccine or treatment designed for this virus. That makes the response more dependent on basic public health measures and on reaching patients early.
Because the virus can move with travelers, cases outside Congo are treated as part of the same emergency. A person can carry the infection across a border before the illness is recognized, which makes early detection important in countries that receive travelers from affected areas. The Kenya and Nigeria cases show why the outbreak cannot be managed only at its origin.
Kenya and Nigeria: two imported pathways
Kenya has nine confirmed infections, including two deaths. The chain began with a patient who left DR Congo, passed through Uganda and arrived in Nairobi. That route underscores how ordinary travel can spread the virus. Kenya’s total is far smaller than Congo’s, but each infection requires a public health response to find and isolate cases and to prevent further spread.
Nigeria’s case is a Swiss woman who is the wife of a Swiss diplomat. She became sick after a trip to Uganda. Investigators are trying to determine where she contracted the virus, a question that matters for tracing the transmission chain. Officials later evacuated her to Switzerland. Nigeria is on alert after the positive test, and the single case shows how one infection can trigger a broad response.
The two countries represent different paths into the outbreak. In Kenya, the link is a patient who came from Congo via Uganda to Nairobi. In Nigeria, the link is travel to Uganda, while the exact source of infection remains under investigation. Both countries face the same tasks: confirm cases quickly, isolate patients and stop further transmission. The outbreak is not centered in either place, but it cannot be contained if imported cases are missed.
Transmission, symptoms and the trials under way
Ebola passes through direct exposure to blood or other body fluids from someone who is infected. Fever and diarrhea are common, and some patients bleed. At first, the illness can look like malaria, which may postpone isolation and care. That diagnostic overlap is dangerous: a patient who is not recognized promptly can remain in contact with family members, health workers and others before diagnosis.
The lack of a Bundibugyo-specific vaccine or treatment makes that challenge worse. Ervebo is licensed and recommended solely for Ebola virus, once called Zaire ebolavirus. Two more trials are testing whether Ervebo can protect people against Bundibugyo. If it works, the vaccine could add a powerful tool; for now, that use remains experimental.
Treatment research is also active. Two antiviral strategies have been in clinical trials since July. These studies are asking whether antiviral medicines can help patients with Bundibugyo. They are not yet proven, and results will take time. In the meantime, the response depends on recognizing cases early, isolating patients and limiting transmission.
The outbreak’s course will hinge on how quickly Congo’s response can slow transmission and how well other countries detect imported infections. The numbers—10,060 cases and 4,887 deaths—show the scale. Kenya and Nigeria show the reach. The antiviral and Ervebo studies may eventually provide better tools, but none is yet established for Bundibugyo. Until then, the response rests on early recognition and rapid isolation. The article was edited by Wesley Rahn.